nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymorphone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0567	0.0809	CbGbCtD
Oxymorphone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0533	0.0761	CbGbCtD
Oxymorphone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0533	0.0761	CbGbCtD
Oxymorphone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0482	0.0688	CbGbCtD
Oxymorphone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0482	0.0688	CbGbCtD
Oxymorphone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0416	0.0594	CbGbCtD
Oxymorphone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0404	0.0576	CbGbCtD
Oxymorphone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0366	0.0521	CbGbCtD
Oxymorphone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0366	0.0521	CbGbCtD
Oxymorphone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0361	0.0514	CbGbCtD
Oxymorphone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0339	0.0484	CbGbCtD
Oxymorphone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0339	0.0484	CbGbCtD
Oxymorphone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0307	0.0437	CbGbCtD
Oxymorphone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0307	0.0437	CbGbCtD
Oxymorphone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0265	0.0378	CbGbCtD
Oxymorphone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0257	0.0367	CbGbCtD
Oxymorphone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0232	0.0331	CbGbCtD
Oxymorphone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0232	0.0331	CbGbCtD
Oxymorphone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0223	0.0318	CbGbCtD
Oxymorphone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00238	0.185	CbGeAlD
Oxymorphone—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00134	0.0289	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00118	0.0253	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00104	0.0224	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000994	0.0214	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000913	0.0196	CbGpPWpGaD
Oxymorphone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000786	0.0609	CbGeAlD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000771	0.0166	CbGpPWpGaD
Oxymorphone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000757	0.0586	CbGeAlD
Oxymorphone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000754	0.0584	CbGeAlD
Oxymorphone—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000749	0.0161	CbGpPWpGaD
Oxymorphone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000734	0.0569	CbGeAlD
Oxymorphone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000726	0.0562	CbGeAlD
Oxymorphone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000723	0.056	CbGeAlD
Oxymorphone—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000704	0.0152	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000698	0.015	CbGpPWpGaD
Oxymorphone—OPRM1—blood—acquired immunodeficiency syndrome	0.00066	0.0512	CbGeAlD
Oxymorphone—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000657	0.0141	CbGpPWpGaD
Oxymorphone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000636	0.0493	CbGeAlD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000631	0.0136	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000618	0.0133	CbGpPWpGaD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000612	0.0132	CbGpPWpGaD
Oxymorphone—OPRD1—brain—acquired immunodeficiency syndrome	0.000601	0.0465	CbGeAlD
Oxymorphone—OPRK1—brain—acquired immunodeficiency syndrome	0.000576	0.0446	CbGeAlD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00057	0.0123	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000555	0.0119	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000553	0.0119	CbGpPWpGaD
Oxymorphone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000536	0.0415	CbGeAlD
Oxymorphone—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000532	0.0114	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000522	0.0112	CbGpPWpGaD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000517	0.0111	CbGpPWpGaD
Oxymorphone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000516	0.04	CbGeAlD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0005	0.0108	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000483	0.0104	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000467	0.0101	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000466	0.01	CbGpPWpGaD
Oxymorphone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000456	0.00981	CbGpPWpGaD
Oxymorphone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000456	0.00981	CbGpPWpGaD
Oxymorphone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000443	0.00954	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000423	0.00911	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000423	0.0091	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000423	0.0091	CbGpPWpGaD
Oxymorphone—OPRM1—brain—acquired immunodeficiency syndrome	0.00041	0.0317	CbGeAlD
Oxymorphone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000394	0.00848	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00039	0.00839	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000383	0.00823	CbGpPWpGaD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000371	0.00798	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000358	0.0077	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000352	0.00758	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000342	0.00735	CbGpPWpGaD
Oxymorphone—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00034	0.00142	CcSEcCtD
Oxymorphone—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000339	0.00142	CcSEcCtD
Oxymorphone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000339	0.00142	CcSEcCtD
Oxymorphone—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000339	0.00142	CcSEcCtD
Oxymorphone—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000339	0.00142	CcSEcCtD
Oxymorphone—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000337	0.00141	CcSEcCtD
Oxymorphone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000337	0.00141	CcSEcCtD
Oxymorphone—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000337	0.00141	CcSEcCtD
Oxymorphone—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000336	0.00141	CcSEcCtD
Oxymorphone—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000336	0.00141	CcSEcCtD
Oxymorphone—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000336	0.0014	CcSEcCtD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000335	0.00722	CbGpPWpGaD
Oxymorphone—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000335	0.0014	CcSEcCtD
Oxymorphone—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000335	0.0014	CcSEcCtD
Oxymorphone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000335	0.0072	CbGpPWpGaD
Oxymorphone—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000334	0.0014	CcSEcCtD
Oxymorphone—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000334	0.00139	CcSEcCtD
Oxymorphone—Headache—Didanosine—acquired immunodeficiency syndrome	0.000332	0.00139	CcSEcCtD
Oxymorphone—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000331	0.00139	CcSEcCtD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000331	0.00713	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000331	0.00713	CbGpPWpGaD
Oxymorphone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000331	0.00138	CcSEcCtD
Oxymorphone—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000331	0.00138	CcSEcCtD
Oxymorphone—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00033	0.00138	CcSEcCtD
Oxymorphone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00033	0.00138	CcSEcCtD
Oxymorphone—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00033	0.00138	CcSEcCtD
Oxymorphone—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000329	0.00138	CcSEcCtD
Oxymorphone—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000329	0.00138	CcSEcCtD
Oxymorphone—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000329	0.00137	CcSEcCtD
Oxymorphone—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000329	0.00137	CcSEcCtD
Oxymorphone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000328	0.00137	CcSEcCtD
Oxymorphone—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000327	0.00137	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000327	0.00137	CcSEcCtD
Oxymorphone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00136	CcSEcCtD
Oxymorphone—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000326	0.00136	CcSEcCtD
Oxymorphone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000326	0.00136	CcSEcCtD
Oxymorphone—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000325	0.00136	CcSEcCtD
Oxymorphone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000325	0.00136	CcSEcCtD
Oxymorphone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000325	0.00136	CcSEcCtD
Oxymorphone—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000324	0.00135	CcSEcCtD
Oxymorphone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000323	0.00135	CcSEcCtD
Oxymorphone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000323	0.00135	CcSEcCtD
Oxymorphone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000322	0.00693	CbGpPWpGaD
Oxymorphone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000322	0.00135	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.00135	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000321	0.00134	CcSEcCtD
Oxymorphone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00032	0.00134	CcSEcCtD
Oxymorphone—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.00032	0.00134	CcSEcCtD
Oxymorphone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.00032	0.00134	CcSEcCtD
Oxymorphone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000318	0.00133	CcSEcCtD
Oxymorphone—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000318	0.00133	CcSEcCtD
Oxymorphone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000318	0.00133	CcSEcCtD
Oxymorphone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000317	0.00133	CcSEcCtD
Oxymorphone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.00133	CcSEcCtD
Oxymorphone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000317	0.00133	CcSEcCtD
Oxymorphone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000316	0.00132	CcSEcCtD
Oxymorphone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000316	0.00132	CcSEcCtD
Oxymorphone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000316	0.00132	CcSEcCtD
Oxymorphone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000316	0.00132	CcSEcCtD
Oxymorphone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000315	0.00132	CcSEcCtD
Oxymorphone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000315	0.00132	CcSEcCtD
Oxymorphone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000314	0.00131	CcSEcCtD
Oxymorphone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000314	0.00131	CcSEcCtD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000314	0.00675	CbGpPWpGaD
Oxymorphone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000313	0.00131	CcSEcCtD
Oxymorphone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000313	0.00131	CcSEcCtD
Oxymorphone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000313	0.00131	CcSEcCtD
Oxymorphone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000312	0.00131	CcSEcCtD
Oxymorphone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.0013	CcSEcCtD
Oxymorphone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000311	0.0013	CcSEcCtD
Oxymorphone—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000311	0.0013	CcSEcCtD
Oxymorphone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00031	0.0013	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.0013	CcSEcCtD
Oxymorphone—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000309	0.00129	CcSEcCtD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000309	0.00665	CbGpPWpGaD
Oxymorphone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000307	0.00128	CcSEcCtD
Oxymorphone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000306	0.00128	CcSEcCtD
Oxymorphone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000306	0.00658	CbGpPWpGaD
Oxymorphone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.00128	CcSEcCtD
Oxymorphone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.00128	CcSEcCtD
Oxymorphone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000305	0.00128	CcSEcCtD
Oxymorphone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000305	0.00127	CcSEcCtD
Oxymorphone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.00127	CcSEcCtD
Oxymorphone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000304	0.00127	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000304	0.00127	CcSEcCtD
Oxymorphone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000304	0.00127	CcSEcCtD
Oxymorphone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000303	0.00127	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.00127	CcSEcCtD
Oxymorphone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000303	0.00127	CcSEcCtD
Oxymorphone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000303	0.00127	CcSEcCtD
Oxymorphone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.00127	CcSEcCtD
Oxymorphone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.00126	CcSEcCtD
Oxymorphone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000301	0.00126	CcSEcCtD
Oxymorphone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.0003	0.00126	CcSEcCtD
Oxymorphone—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.0003	0.00126	CcSEcCtD
Oxymorphone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.0003	0.00126	CcSEcCtD
Oxymorphone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.0003	0.00125	CcSEcCtD
Oxymorphone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.0003	0.00125	CcSEcCtD
Oxymorphone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000299	0.00125	CcSEcCtD
Oxymorphone—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000299	0.00125	CcSEcCtD
Oxymorphone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000299	0.00125	CcSEcCtD
Oxymorphone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000298	0.00125	CcSEcCtD
Oxymorphone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000298	0.00124	CcSEcCtD
Oxymorphone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000297	0.0064	CbGpPWpGaD
Oxymorphone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.00124	CcSEcCtD
Oxymorphone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000296	0.00124	CcSEcCtD
Oxymorphone—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000296	0.00124	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.00124	CcSEcCtD
Oxymorphone—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000295	0.00123	CcSEcCtD
Oxymorphone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000294	0.00123	CcSEcCtD
Oxymorphone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000294	0.00123	CcSEcCtD
Oxymorphone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000294	0.00123	CcSEcCtD
Oxymorphone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.00123	CcSEcCtD
Oxymorphone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000293	0.00123	CcSEcCtD
Oxymorphone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000292	0.00122	CcSEcCtD
Oxymorphone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000292	0.00122	CcSEcCtD
Oxymorphone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000291	0.00627	CbGpPWpGaD
Oxymorphone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000291	0.00122	CcSEcCtD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000291	0.00625	CbGpPWpGaD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000291	0.00625	CbGpPWpGaD
Oxymorphone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00029	0.00121	CcSEcCtD
Oxymorphone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000289	0.00121	CcSEcCtD
Oxymorphone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.00121	CcSEcCtD
Oxymorphone—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000289	0.00121	CcSEcCtD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000289	0.00621	CbGpPWpGaD
Oxymorphone—Headache—Stavudine—acquired immunodeficiency syndrome	0.000288	0.0012	CcSEcCtD
Oxymorphone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000288	0.0012	CcSEcCtD
Oxymorphone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000288	0.0012	CcSEcCtD
Oxymorphone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000287	0.0012	CcSEcCtD
Oxymorphone—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000287	0.0012	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000287	0.0012	CcSEcCtD
Oxymorphone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000287	0.0012	CcSEcCtD
Oxymorphone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000285	0.00119	CcSEcCtD
Oxymorphone—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.00119	CcSEcCtD
Oxymorphone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000285	0.00119	CcSEcCtD
Oxymorphone—Headache—Abacavir—acquired immunodeficiency syndrome	0.000284	0.00119	CcSEcCtD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000284	0.0061	CbGpPWpGaD
Oxymorphone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000283	0.00118	CcSEcCtD
Oxymorphone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000283	0.00118	CcSEcCtD
Oxymorphone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000282	0.00608	CbGpPWpGaD
Oxymorphone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000282	0.0219	CbGeAlD
Oxymorphone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.00117	CcSEcCtD
Oxymorphone—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.00117	CcSEcCtD
Oxymorphone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00028	0.00117	CcSEcCtD
Oxymorphone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00028	0.00601	CbGpPWpGaD
Oxymorphone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00028	0.00601	CbGpPWpGaD
Oxymorphone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.00117	CcSEcCtD
Oxymorphone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000279	0.00117	CcSEcCtD
Oxymorphone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000278	0.0215	CbGeAlD
Oxymorphone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000278	0.00116	CcSEcCtD
Oxymorphone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000278	0.00116	CcSEcCtD
Oxymorphone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.00116	CcSEcCtD
Oxymorphone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000277	0.00116	CcSEcCtD
Oxymorphone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000277	0.00116	CcSEcCtD
Oxymorphone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000276	0.00115	CcSEcCtD
Oxymorphone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000276	0.00594	CbGpPWpGaD
Oxymorphone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.00115	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.00115	CcSEcCtD
Oxymorphone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000274	0.00115	CcSEcCtD
Oxymorphone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000274	0.00114	CcSEcCtD
Oxymorphone—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00114	CcSEcCtD
Oxymorphone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000273	0.00114	CcSEcCtD
Oxymorphone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000273	0.00114	CcSEcCtD
Oxymorphone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000273	0.00587	CbGpPWpGaD
Oxymorphone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000272	0.00114	CcSEcCtD
Oxymorphone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00027	0.00113	CcSEcCtD
Oxymorphone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.00113	CcSEcCtD
Oxymorphone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000269	0.0208	CbGeAlD
Oxymorphone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000269	0.00112	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.00112	CcSEcCtD
Oxymorphone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.00112	CcSEcCtD
Oxymorphone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.00112	CcSEcCtD
Oxymorphone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00111	CcSEcCtD
Oxymorphone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000267	0.00111	CcSEcCtD
Oxymorphone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000267	0.00111	CcSEcCtD
Oxymorphone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000266	0.00111	CcSEcCtD
Oxymorphone—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000266	0.00111	CcSEcCtD
Oxymorphone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000266	0.00111	CcSEcCtD
Oxymorphone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.00111	CcSEcCtD
Oxymorphone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.00111	CcSEcCtD
Oxymorphone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000265	0.0205	CbGeAlD
Oxymorphone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000264	0.0011	CcSEcCtD
Oxymorphone—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.0011	CcSEcCtD
Oxymorphone—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000263	0.0011	CcSEcCtD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000261	0.00562	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000261	0.00562	CbGpPWpGaD
Oxymorphone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000261	0.00561	CbGpPWpGaD
Oxymorphone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00109	CcSEcCtD
Oxymorphone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000259	0.00558	CbGpPWpGaD
Oxymorphone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.00108	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.00108	CcSEcCtD
Oxymorphone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00108	CcSEcCtD
Oxymorphone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.00108	CcSEcCtD
Oxymorphone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000256	0.00107	CcSEcCtD
Oxymorphone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000256	0.00107	CcSEcCtD
Oxymorphone—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000256	0.00107	CcSEcCtD
Oxymorphone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000255	0.0055	CbGpPWpGaD
Oxymorphone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000254	0.00106	CcSEcCtD
Oxymorphone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000254	0.00106	CcSEcCtD
Oxymorphone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000254	0.00106	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.00106	CcSEcCtD
Oxymorphone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000254	0.00106	CcSEcCtD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000252	0.00542	CbGpPWpGaD
Oxymorphone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00105	CcSEcCtD
Oxymorphone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000252	0.00105	CcSEcCtD
Oxymorphone—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00105	CcSEcCtD
Oxymorphone—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00025	0.00105	CcSEcCtD
Oxymorphone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000248	0.00104	CcSEcCtD
Oxymorphone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00104	CcSEcCtD
Oxymorphone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000248	0.00103	CcSEcCtD
Oxymorphone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.00103	CcSEcCtD
Oxymorphone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.00103	CcSEcCtD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000246	0.00528	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000246	0.00528	CbGpPWpGaD
Oxymorphone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000245	0.00527	CbGpPWpGaD
Oxymorphone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000245	0.00527	CbGpPWpGaD
Oxymorphone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000245	0.00102	CcSEcCtD
Oxymorphone—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.00102	CcSEcCtD
Oxymorphone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.00102	CcSEcCtD
Oxymorphone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000242	0.00521	CbGpPWpGaD
Oxymorphone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00101	CcSEcCtD
Oxymorphone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.001	CcSEcCtD
Oxymorphone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000239	0.00515	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000239	0.00514	CbGpPWpGaD
Oxymorphone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.000994	CcSEcCtD
Oxymorphone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.000993	CcSEcCtD
Oxymorphone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000237	0.000992	CcSEcCtD
Oxymorphone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000988	CcSEcCtD
Oxymorphone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000988	CcSEcCtD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000236	0.00509	CbGpPWpGaD
Oxymorphone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000236	0.000988	CcSEcCtD
Oxymorphone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000235	0.000983	CcSEcCtD
Oxymorphone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000234	0.000979	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000975	CcSEcCtD
Oxymorphone—Headache—Indinavir—acquired immunodeficiency syndrome	0.000233	0.000973	CcSEcCtD
Oxymorphone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000232	0.000971	CcSEcCtD
Oxymorphone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.000961	CcSEcCtD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000229	0.00493	CbGpPWpGaD
Oxymorphone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.000957	CcSEcCtD
Oxymorphone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000227	0.00489	CbGpPWpGaD
Oxymorphone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000227	0.00489	CbGpPWpGaD
Oxymorphone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.000947	CcSEcCtD
Oxymorphone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000943	CcSEcCtD
Oxymorphone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000943	CcSEcCtD
Oxymorphone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000223	0.000933	CcSEcCtD
Oxymorphone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.000932	CcSEcCtD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000222	0.00478	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000222	0.00478	CbGpPWpGaD
Oxymorphone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000222	0.000929	CcSEcCtD
Oxymorphone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000221	0.000925	CcSEcCtD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000221	0.00476	CbGpPWpGaD
Oxymorphone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000221	0.000923	CcSEcCtD
Oxymorphone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00022	0.00474	CbGpPWpGaD
Oxymorphone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.000921	CcSEcCtD
Oxymorphone—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00022	0.00092	CcSEcCtD
Oxymorphone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.000919	CcSEcCtD
Oxymorphone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000218	0.0169	CbGeAlD
Oxymorphone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000216	0.00465	CbGpPWpGaD
Oxymorphone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000215	0.0166	CbGeAlD
Oxymorphone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.000897	CcSEcCtD
Oxymorphone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000893	CcSEcCtD
Oxymorphone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000213	0.00458	CbGpPWpGaD
Oxymorphone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.000889	CcSEcCtD
Oxymorphone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000212	0.000885	CcSEcCtD
Oxymorphone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000884	CcSEcCtD
Oxymorphone—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00021	0.00088	CcSEcCtD
Oxymorphone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00021	0.0163	CbGeAlD
Oxymorphone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000879	CcSEcCtD
Oxymorphone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.000872	CcSEcCtD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000207	0.00446	CbGpPWpGaD
Oxymorphone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000207	0.00446	CbGpPWpGaD
Oxymorphone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000207	0.00446	CbGpPWpGaD
Oxymorphone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000207	0.016	CbGeAlD
Oxymorphone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000205	0.000859	CcSEcCtD
Oxymorphone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.000856	CcSEcCtD
Oxymorphone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000855	CcSEcCtD
Oxymorphone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000204	0.0044	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000202	0.00435	CbGpPWpGaD
Oxymorphone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.000844	CcSEcCtD
Oxymorphone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.000834	CcSEcCtD
Oxymorphone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000199	0.00428	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000199	0.00428	CbGpPWpGaD
Oxymorphone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000198	0.000827	CcSEcCtD
Oxymorphone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.000826	CcSEcCtD
Oxymorphone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.000818	CcSEcCtD
Oxymorphone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000816	CcSEcCtD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000195	0.00419	CbGpPWpGaD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000195	0.00419	CbGpPWpGaD
Oxymorphone—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.000814	CcSEcCtD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000194	0.00417	CbGpPWpGaD
Oxymorphone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000192	0.00414	CbGpPWpGaD
Oxymorphone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000192	0.00413	CbGpPWpGaD
Oxymorphone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000192	0.00412	CbGpPWpGaD
Oxymorphone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.000795	CcSEcCtD
Oxymorphone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000189	0.000789	CcSEcCtD
Oxymorphone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.000787	CcSEcCtD
Oxymorphone—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000187	0.000783	CcSEcCtD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000187	0.00402	CbGpPWpGaD
Oxymorphone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000186	0.00401	CbGpPWpGaD
Oxymorphone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.000771	CcSEcCtD
Oxymorphone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.000758	CcSEcCtD
Oxymorphone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00018	0.00387	CbGpPWpGaD
Oxymorphone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.000751	CcSEcCtD
Oxymorphone—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.000747	CcSEcCtD
Oxymorphone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000178	0.00383	CbGpPWpGaD
Oxymorphone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000743	CcSEcCtD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000175	0.00377	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000175	0.00376	CbGpPWpGaD
Oxymorphone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.000708	CcSEcCtD
Oxymorphone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000169	0.00364	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000169	0.00364	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000169	0.00364	CbGpPWpGaD
Oxymorphone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000168	0.00362	CbGpPWpGaD
Oxymorphone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000168	0.00361	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000165	0.00356	CbGpPWpGaD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000165	0.00354	CbGpPWpGaD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000165	0.00354	CbGpPWpGaD
Oxymorphone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000164	0.0127	CbGeAlD
Oxymorphone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000161	0.00347	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000158	0.0034	CbGpPWpGaD
Oxymorphone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000158	0.00339	CbGpPWpGaD
Oxymorphone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000156	0.00335	CbGpPWpGaD
Oxymorphone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000152	0.00328	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00015	0.00322	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000148	0.00319	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000148	0.00319	CbGpPWpGaD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000148	0.00319	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000147	0.00317	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000145	0.00312	CbGpPWpGaD
Oxymorphone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000142	0.00306	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000141	0.00304	CbGpPWpGaD
Oxymorphone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000134	0.00287	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000133	0.00287	CbGpPWpGaD
Oxymorphone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000132	0.00284	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000131	0.00282	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000129	0.00277	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000125	0.0027	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000125	0.0027	CbGpPWpGaD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000125	0.0027	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000123	0.00264	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000119	0.00257	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000116	0.0025	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000113	0.00243	CbGpPWpGaD
Oxymorphone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000113	0.00243	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000111	0.00238	CbGpPWpGaD
Oxymorphone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000104	0.00224	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000102	0.0022	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000102	0.00219	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000102	0.00219	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.77e-05	0.0021	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.77e-05	0.0021	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.56e-05	0.00206	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.56e-05	0.00206	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.54e-05	0.00205	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.24e-05	0.00199	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.96e-05	0.00193	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.92e-05	0.00192	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.83e-05	0.0019	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.68e-05	0.00187	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.68e-05	0.00187	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.6e-05	0.00185	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.56e-05	0.00184	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.56e-05	0.00184	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.39e-05	0.0018	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.39e-05	0.0018	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.1e-05	0.00174	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.74e-05	0.00167	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.62e-05	0.00164	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.62e-05	0.00164	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.57e-05	0.00163	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.54e-05	0.00162	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.28e-05	0.00157	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.24e-05	0.00156	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.24e-05	0.00156	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.17e-05	0.00154	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.09e-05	0.00153	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.09e-05	0.00153	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.85e-05	0.00147	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.61e-05	0.00142	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.55e-05	0.00141	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.55e-05	0.00141	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.51e-05	0.0014	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.44e-05	0.00139	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.44e-05	0.00139	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.38e-05	0.00137	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.28e-05	0.00135	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.03e-05	0.0013	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.95e-05	0.00128	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.79e-05	0.00125	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.75e-05	0.00124	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.71e-05	0.00123	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	5.63e-05	0.00121	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.46e-05	0.00117	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.39e-05	0.00116	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.31e-05	0.00114	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.29e-05	0.00114	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.22e-05	0.00112	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.13e-05	0.0011	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.13e-05	0.0011	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.9e-05	0.00105	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.86e-05	0.00105	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.82e-05	0.00104	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	4.79e-05	0.00103	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.78e-05	0.00103	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.5e-05	0.000968	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.5e-05	0.000968	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.47e-05	0.000962	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.41e-05	0.000949	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.04e-05	0.00087	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.9e-05	0.00084	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.84e-05	0.000827	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.8e-05	0.000818	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.8e-05	0.000818	CbGpPWpGaD
Oxymorphone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.79e-05	0.000815	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.68e-05	0.000792	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.52e-05	0.000757	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.44e-05	0.00074	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.000736	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.000725	CbGpPWpGaD
Oxymorphone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.32e-05	0.000715	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.13e-05	0.000673	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.000664	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.02e-05	0.000649	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.89e-05	0.000622	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.85e-05	0.000613	CbGpPWpGaD
Oxymorphone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.81e-05	0.000604	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000561	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.55e-05	0.000548	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.03e-05	0.000437	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.02e-05	0.000435	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000383	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.77e-05	0.000381	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.51e-05	0.000324	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.5e-05	0.000322	CbGpPWpGaD
Oxymorphone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000257	CbGpPWpGaD
Oxymorphone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000225	CbGpPWpGaD
Oxymorphone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	9.82e-06	0.000211	CbGpPWpGaD
Oxymorphone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.85e-06	0.00019	CbGpPWpGaD
Oxymorphone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	6.42e-06	0.000138	CbGpPWpGaD
